日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
World
Home / World / Americas

US steps up clinical trials for COVID-19 treatment

Xinhua | Updated: 2020-08-07 07:38
Share
Share - WeChat

WASHINGTON -- The US National Institutes of Health (NIH) announced on Thursday the start of a randomized, controlled clinical trial evaluating the safety and efficacy of a treatment regimen consisting of the antiviral remdesivir plus the immunomodulator interferon beta-1a in COVID-19 patients.

A nurse wearing personal protective equipment watches an ambulance driving away outside of Elmhurst Hospital during the ongoing outbreak of the coronavirus disease (COVID-19) in the Queens borough of New York, US, April 20, 2020. [Photo/Agencies]

The study, called the Adaptive COVID-19 Treatment Trial 3 (ACTT 3), is anticipated to enroll more than 1,000 hospitalized adults with COVID-19 at as many as 100 sites in the United States and abroad, according to a release of the NIH.

It is the second clinical trial announced by the NIH this week in an effort to step up treatment for COVID-19.

Participants must have laboratory-confirmed SARS-CoV-2 infection with evidence of lung involvement, including a need for supplemental oxygen, abnormal chest X-rays, or illness requiring mechanical ventilation. People with confirmed infection who have mild symptoms or no apparent symptoms will not be included in the study, said the NIH.

They are being randomly assigned in a 1-to-1 ratio to receive either subcutaneous interferon beta-1a plus remdesivir (combination therapy) or remdesivir alone. Neither the participants nor the study team will know who is receiving which treatment regimen.

All participants will receive standard doses of remdesivir and either interferon beta-1a or a placebo. Those in the combination therapy group will receive interferon beta-1a as a 44-microgram subcutaneous injection every other day for a total of four doses during hospitalization.

Those in the remdesivir-only group will receive a matching placebo subcutaneous injection every other day for a total of four doses during hospitalization.

Investigators will evaluate whether time to recovery is shorter in the combination therapy group relative to the remdesivir-only group, said the NIH.

1 2 Next   >>|
Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 日韩免费在线观看视频 | 天堂热 | 成人精品在线观看 | 欧美又黄又嫩大片a级 | 日本一级成人毛片免费观看 | 日韩在线免费播放 | 国产AV亚洲精品久久久久 | 亚欧乱色一区二区三区 | 成人国内精品久久久久影院 | 555夜色666夜色精品站 | 新超碰97 | 激情小说激情图片激情电影 | 日韩毛片高清免费 | 成人久久一区二区 | www.国产 | 亚洲精品乱码久久久久久v 国产高清免费视频 | 久久99亚洲综合精品首页 | 亚洲狠狠婷婷综合久久久久图片 | 日韩h片在线观看 | 久久天天躁夜夜躁狠狠 | 亚洲国产精品久久久久网站 | 777久久婷婷成人综合色 | 四虎国产成人免费观看 | 日韩18在线观看地址 | 波多野结衣全部系列在线观看 | 韩国理论午夜 | 男女免费视频网站 | 97久久国语露脸精品对白 | 亚洲欧美激情另类 | 一区二区三区在线 | 在线日韩精品视频 | 色99色 | 国产精品亚洲片在线va | 青娱在线视频 | 欧美三级 欧美一级 | 日韩国产午夜一区二区三区 | 欧美永久免费 | 99精品国产免费久久国语 | 日本青草视频 | 国产精品中文字幕在线 | 99在线精品视频免费观里 |